The United States Patent and Trademark Office (USPTO) issued an important update to its guidance on patent subject matter eligibility under 35 U.S.C. § 101, specifically focusing on artificial intelligence (AI) and other...more
7/26/2024
/ Abstract Ideas ,
Artificial Intelligence ,
Corporate Counsel ,
Emerging Technology Companies ,
Enforcement ,
Inventions ,
Patent Infringement ,
Patent-Eligible Subject Matter ,
Patents ,
Technology Sector ,
USPTO
The United States Patent and Trademark Office (USPTO) has issued a pivotal guidance document, effective April 11, on the use of Artificial Intelligence (AI) tools within patent and trademark practices. This guidance signals a...more
Pursuant to President Biden’s October 2023 executive order on AI, on April 11, 2024, the United States Patent and Trademark Office (USPTO or Office) published “Guidance on Use of Artificial Intelligence-Based Tools in...more
4/23/2024
/ Artificial Intelligence ,
Biden Administration ,
Confidential Information ,
Executive Orders ,
Exports ,
Inventions ,
Inventors ,
Licensing Rules ,
Machine Learning ,
New Guidance ,
Patents ,
Policies and Procedures ,
Regulatory Agenda ,
Regulatory Requirements ,
USPTO
A “picture” claim refers to a patent claim precisely tailored to track a particular product’s important advantages and features. When drafting a patent application, one should describe various embodiments of the invention and...more
On May 19, 2023, the Supreme Court in Amgen v. Sanofi, No. 21-757, unanimously held that the claims of two Amgen patents, both directed to a genus of potentially millions of antibodies, are invalid because the patents failed...more
Overview of Subject Matter Eligibility Challenges Computer-based -
inventions – especially in the machine learning (ML), bioinformatics, and artificial intelligence (AI) fields – are susceptible to subject matter...more
Machine learning (ML), bioinformatics, artificial intelligence (AI), and other computational tools have become ubiquitous in the biotech and synthetic biology industries because such technology allows for rapid processing of...more
In our first blog in this multi-part series, we explored key considerations for protecting artificial intelligence (“AI”) inventions in biotech and synthetic biology. In this part 2 of the series, we will examine some key...more
1/30/2020
/ Algorithms ,
Artificial Intelligence ,
Biotechnology ,
Computer-Related Inventions ,
Intellectual Property Protection ,
Life Sciences ,
Machine Learning ,
Patent Applications ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
USPTO
Artificial Intelligence (AI) inventions have aided development in nearly every industry, but perhaps none more so than synthetic biology. For synthetic biology researchers, AI has developed into a vital tool to create cutting...more
9/30/2019
/ Analytics ,
Artificial Intelligence ,
Biotechnology ,
Computer-Related Inventions ,
CRISPR ,
Drug Compounding ,
Intellectual Property Protection ,
Machine Learning ,
Patent Prosecution ,
Patents ,
Pharmaceutical Patents ,
Popular ,
Robotics ,
Software Patents ,
USPTO
On June 19, 2017, the U.S. Patent and Trademark Office (USPTO) announced that it would be extending the Cancer Immunotherapy Pilot Program, which permits patent applications pertaining to cancer immunotherapy to be examined...more
Effective June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented a pilot program to provide for earlier review of patent applications pertaining to cancer immunotherapy. The Cancer Immunotherapy...more
Patent applicants who have filed a priority application (such as a U.S. Provisional application) may wish to abandon and then refile that priority application to extend the time available for filing a utility application. ...more
6/30/2016
/ Abandonment ,
Effective Filing Date ,
European Patent Convention ,
Industrial Design ,
Paris Convention ,
Patent Applications ,
Patents ,
Priority Disputes ,
Refiling ,
Trademarks ,
Utility Patents
On June 12, 2015, the Federal Circuit affirmed the finding of U.S. District Court for the Northern District of California (“District Court”) that the method claims in U.S. Patent 6,258,540 (‘540 patent) for detecting...more
On June 12, 2015, in Ariosa Diagnostics, Inc. v. Sequenom, Inc., the Federal Circuit affirmed the Northern District of California’s finding that the method claims in U.S. Patent 6,258,540 (‘540 patent) for detecting...more
In an order released on March 19, 2015, U.S. District Court Judge Richard Seeborg of the Northern District of California denied Amgen’s motion for judgment on the pleadings as well as its request for a preliminary injunction...more
The Leahy-Smith America Invents Act (AIA) was signed into law on September 16, 2011. While the AIA alters U.S. patent practice in several ways, perhaps the most significant change brought about by the law is the switch from a...more